Table 4 Standardised incidence ratios and absolute excess risks of subsequent breast cancer among patients with bone sarcoma by calendar year at diagnosis, age at diagnosis, site and follow-up.

Calendar Year

 1958–1979

11/4.0

2.7

(1.4–4.9)

21.6

(4.6–48.4)

8/3.3

2.4

(1.1–4.8)

19.7

(0.7–52.1)

3/0.7

4.2

(0.9–12.3)

27.0

(−1.1 to 95.2)

 1980–1999

6/2.4

2.5

(0.9–5.5)

13.2

(−0.6 to 38.8)

3/1.9

1.6

(0.3–4.6)

5.6

(−6.6 too 35.2)

3/0.5

6.5

(1.3–19.1)

31.4

(2.0–103)

 2000–2015

1/0.8

1.3

(0.0–7.5)

2.2

(−6.2 to 41.3)

1/0.6

1.6

(0.0–8.7)

4.7

(−8.0 to 64.1)

0/0.1

-

-

Age at diagnosis

 0–9 years

1/0.2

6.7

(0.2–37.5)

9.6

(−1.4 to 61.2)

0/0.1

-

-

1/0.1

11.9

(0.3–66.3)

17.4

(−1.1 to 104)

 10–19 years

7/1.8

3.9

(1.5–7.9)

15.2

(2.9–36.9)

4/1.4

2.8

(0.8–7.2)

10.4

(−1.3 to 35.4)

3/0.4

7.4

(1.5–21.8)

28.1

(2.3–90.5)

 ≥20 years

10/5.1

1.9

(0.9–3.6)

17.0

(−1.2 to 46.2)

8/4.4

1.8

(0.8–3.6)

16.2

(−4.0 to 50.5)

2/0.8

2.5

(0.3–9.1)

20.0

(−9.1 to 106)

Site

 Extremity

13/6.2

2.1

(1.1–3.6)

11.4

(1.2–26.8)

10/5.3

1.9

(0.9–3.5)

10.2

(−1.0 to 28.2)

3/0.9

3.2

(0.7–9.3)

15.5

(−2.5 to 59.0)

 Central

5/0.8

6.5

(2.1–15.2)

40.5

(8.2–104)

2/0.4

4.6

(0.6–16.5)

48.3

(−6.0 to 210)

3/0.3

9.0

(1.9–26.4)

36.9

(4.0–117)

 Pelvic

1/0.2

4.6

(0.1–25.4)

20.8

(−5.2 to 143)

1/0.2

6.9

(0.2–38.3)

67.7

(−9.5 to 430)

0/0.1

–

–

 Non-pelvic central

4/0.6

7.3

(2.0–18.6)

51.4

(8.1–144)

1/0.3

3.4

(0.1–19.1)

35.9

(−13.5 to 268)

3/0.3

11.6

(2.4–34.0)

57.9

(7.6–180)

Follow-up, years

 0–5

3/1.2

2.6

(0.5–7.6)

8.7

(−2.5 to 35.8)

2/1.0

2.0

(0.2–7.1)

6.8

(−5.3 to 42.9)

1/0.1

7.3

(0.2–40.7)

12.7

(−1.6 to 80.3)

 5–30

9/3.7

2.5

(1.1–4.7)

12.6

(1.1–31.7)

7/3.0

2.3

(0.9–4.8)

13.1

(−0.7 to 37.4)

2/0.7

3.1

(0.4–11.0)

11.4

(−3.5 to 55.7)

 >30

6/2.3

2.6

(1.0–5.7)

45.5

(−1.0 to 132)

3/1.8

1.7

(0.3–4.9)

19.5

(−19.1 to 113)

3/0.5

6.1

(1.3–17.9)

127

(6.6–419)